Fastly, Inc. (FSLY)
NYSE: FSLY · Real-Time Price · USD
6.36
-0.43 (-6.33%)
At close: Aug 1, 2025, 4:00 PM
6.35
-0.01 (-0.16%)
After-hours: Aug 1, 2025, 7:52 PM EDT
Verve Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts that cover Verve Therapeutics stock have a consensus rating of "Hold" and an average price target of $8.31, which forecasts a 30.66% increase in the stock price over the next year. The lowest target is $6.00 and the highest is $12.
Price Target: $8.31 (+30.66%)
Analyst Consensus: Hold
* Price targets were last updated on May 8, 2025.
Analyst Ratings
The average analyst rating for Verve Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 8 | 8 | 8 | 8 | 9 | 9 |
| Sell | 1 | 1 | 1 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 9 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Keybanc | Keybanc | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Jun 6, 2025 |
| RBC Capital | RBC Capital | Hold Maintains $5 → $6 | Hold | Maintains | $5 → $6 | -5.66% | May 8, 2025 |
| Piper Sandler | Piper Sandler | Hold Maintains $6 → $7 | Hold | Maintains | $6 → $7 | +10.06% | May 8, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $7 → $8 | Hold | Maintains | $7 → $8 | +25.79% | May 8, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $8 → $7 | Hold | Maintains | $8 → $7 | +10.06% | Apr 16, 2025 |
Financial Forecast
Revenue This Year
601.68M
from 543.68M
Increased by 10.67%
Revenue Next Year
642.84M
from 601.68M
Increased by 6.84%
EPS This Year
-0.10
from -1.14
EPS Next Year
-0.00
from -0.10
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 620.7M | 676.5M | 731.9M | ||
| Avg | 601.7M | 642.8M | 685.1M | ||
| Low | 573.3M | 604.6M | 634.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 14.2% | 12.4% | 13.8% | ||
| Avg | 10.7% | 6.8% | 6.6% | ||
| Low | 5.4% | 0.5% | -1.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.01 | 0.09 | 0.15 | ||
| Avg | -0.10 | -0.00 | 0.10 | ||
| Low | -0.14 | -0.13 | 0.06 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.